肌内注射与口服双氯芬酸治疗急诊成人急性肌肉骨骼损伤疼痛:前瞻性、双盲、双模拟、随机对照试验
该前瞻性、双盲、双模拟随机对照试验在卡塔尔多哈哈马德总医院急诊科于2018年1月至6月开展,纳入18-65岁、急性肌肉骨骼损伤24小时内就诊、分诊数字评分数值≥5的成人300例,随机接受肌内注射双氯芬酸75 mg加口服安慰剂或口服双氯芬酸100 mg加肌内注射安慰剂。主要终点为用药后30分钟疼痛评分降低≥50%的比例,肌内注射组为99.3%(95%CI 96.3-100),口服组为86.7%(95%CI 80.2-91.7),绝对风险差12.7%,需治疗人数8例(95%CI 6-14)。两组均未发生不良事件。作者结论认为肌内注射双氯芬酸较口服起效更快,但考虑到肌内注射所需准备,临床情况允许选择时口服给药可能更可取。
要点
- 急性肌肉骨骼损伤成人(18-65岁、24小时内就诊、数字评分≥5)中,肌内注射双氯芬酸75 mg组30分钟疼痛降低≥50%的比例为99.3%(95%CI 96.3-100),口服双氯芬酸100 mg组为86.7%(95%CI 80.2-91.7)。
- 绝对风险差为12.7%,需治疗人数8例(95%CI 6-14)接受肌内注射而非口服双氯芬酸才能在30分钟内多获得1例50%疼痛缓解。
- 两组均未报告不良事件。
- 作者结论认为肌内注射双氯芬酸较口服起效更快,但考虑到肌内注射所需准备,临床情况允许选择时口服给药可能更可取。
适用人群与场景
- 18-65岁成人,因急性肌肉骨骼损伤在伤后24小时内至急诊科就诊,分诊时数字评分量表疼痛评分≥5分。
诊断标准与关键阈值
- 分诊疼痛评分采用数字评分量表,评分≥5分作为纳入标准。
处置流程与药物剂量
- 肌内注射组:双氯芬酸75 mg肌内注射加口服安慰剂。
- 口服组:双氯芬酸100 mg口服加肌内注射安慰剂。
研究设计与关键结果
- 前瞻性、双盲、双模拟、随机对照试验,在卡塔尔多哈哈马德总医院急诊科于2018年1月至6月开展,纳入300例参与者(肌内注射组150例,口服组150例)。
- 主要终点用药后30分钟疼痛评分降低≥50%的比例:肌内注射组99.3%(95%CI 96.3-100),口服组86.7%(95%CI 80.2-91.7),绝对风险差12.7%。
- 需治疗人数8例(95%CI 6-14)接受肌内注射而非口服双氯芬酸以在30分钟内多获得1例50%疼痛缓解。
- 两组均未发生不良事件。
证据类型、等级与局限
- 证据类型:前瞻性、双盲、双模拟、随机对照试验。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者结论认为肌内注射双氯芬酸较口服起效更快;但考虑到肌内注射所需准备,临床情况允许选择时口服给药可能更可取。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: The current study aimed to ascertain differences in early postmedication pain reduction in participants presenting with acute musculoskeletal injuries (MSI) to the ED receiving intramuscular (IM) versus per oral (PO) diclofenac.
METHODS: This was a prospective, double-blinded, randomised controlled trial conducted between January and June 2018 at the ED of Hamad General Hospital in Doha, Qatar. Adults (18-65 years of age) presenting to the ED within 24 hours of an acute MSI, who had a triage pain score measured using numerical rating scale of at least five or above were enrolled in this trial. Participants randomised to either IM (75 mg) with oral placebo, or oral (100 mg) diclofenac group with IM placebo using a computer-generated randomised concealed list in blocks of six and eight. The primary objective was to compare the proportion of IM versus PO participants attaining a 50% reduction in pain score at 30 min from t0.
RESULTS: 300 participants were enrolled (150 in the IM diclofenac group and 150 in the PO diclofenac group) in the trial. The primary outcome was achieved in 99.3 (95% CI 96.3 to 100) in the IM group and 86.7 (95% CI 80.2 to 91.7) in PO group. There was an absolute risk difference of 12.7%. This corresponds to a number needed to treat of 8 cases (95% CI 6 to 14) receiving IM rather than the PO diclofenac in order to achieve one additional case of 50% pain reduction within 30 min of drug administration. There were no adverse events experienced in any treatment groups.
CONCLUSION: IM diclofenac injection provides rapid analgesia over PO administration of diclofenac. However, given the preparation needed for an IM injection, oral administration may be preferable when and if clinical circumstances allow a choice in non-steroidal anti-inflammatory drug administration route.
参考来源
- Qureshi I, Pathan SA, Qureshi RS, et al. Intramuscular versus oral diclofenac for acute pain in adults with acute musculoskeletal injuries presenting to the ED setting: a prospective, double-blind, double-dummy, randomised controlled trial. Emerg Med J. 2019. PMID: 31217178. doi:10.1136/emermed-2018-208214
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。